{"protocolSection":{"identificationModule":{"nctId":"NCT02275312","orgStudyIdInfo":{"id":"A-92-52120-192"},"organization":{"fullName":"Ipsen","class":"INDUSTRY"},"briefTitle":"ETREAT Study on Effectiveness of Botulinum Toxin Type A Injections to Treat Post-stroke Upper and/or Lower Limb Spasticity","officialTitle":"ETREAT: A Prospective Observational Study to Evaluate the Effectiveness of Botulinum Toxin Type A (BoNT-A) Injections in Patients With Post-stroke Upper and/or Lower Limb Spasticity in the Early Stage of Spasticity Development.","acronym":"ETREAT"},"statusModule":{"statusVerifiedDate":"2019-08","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2014-07","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2017-07","type":"ACTUAL"},"completionDateStruct":{"date":"2017-07","type":"ACTUAL"},"studyFirstSubmitDate":"2014-10-23","studyFirstSubmitQcDate":"2014-10-23","studyFirstPostDateStruct":{"date":"2014-10-27","type":"ESTIMATED"},"lastUpdateSubmitDate":"2019-08-14","lastUpdatePostDateStruct":{"date":"2019-08-16","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Ipsen","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The objective of this study is to evaluate the effectiveness of BoNT-A on functional improvement in patients with post-stroke upper and/or lower limb spasticity in the early stage of spasticity development, according to routine clinical practice."},"conditionsModule":{"conditions":["Spasticity"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"OTHER","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":110,"type":"ACTUAL"}},"outcomesModule":{"primaryOutcomes":[{"measure":"Change in Goal Attainment Scale (GAS) score.","timeFrame":"Baseline, 16 months"}],"secondaryOutcomes":[{"measure":"Spasticity patterns will be defined in patients with upper and/or lower limb spasticity in the early stage after stroke","description":"Descriptive statistics will be presented in addition to 95% confidence intervals for the mean and percentages","timeFrame":"Baseline, 16 months"},{"measure":"Change in Modified Ashworth Scale (MAS) score.","timeFrame":"Baseline, 16 months"},{"measure":"Baseline characteristics of patients","description":"Demographic characteristics","timeFrame":"Baseline"},{"measure":"Percentage of patients reporting functional improvement evaluated by Goal Attainment Scale (GAS) score.","timeFrame":"From baseline up to 16 months"},{"measure":"Change in pain according to Visual Analog Scale (VAS).","timeFrame":"Baseline, 16 months"},{"measure":"Passive function of upper and/or lower limbs according to primary treatment target (PTT) from the disability assessment scale (DAS).","timeFrame":"Baseline, 16 months"},{"measure":"Comfortable barefoot walking speed, measured with the 10-meter walking speed test.","timeFrame":"Baseline, 16 months"},{"measure":"Change on EQ-5D quality of life questionnaire","timeFrame":"Baseline, 16 months"},{"measure":"Estimation of use of healthcare resources and costs associated with management of spasticity.","timeFrame":"From baseline up to 16 months"},{"measure":"Time interval between injections","timeFrame":"From baseline up to 16 months"},{"measure":"Cost per patient","timeFrame":"From baseline up to 16 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Men and women ≥ 18-80 years.\n* Poststroke limb spasticity.\n* Patients who have suffered a stroke in the previous 6 months.\n* Treatment goal has been previously agreed with the patient or their legal representative.\n* Patients with clinically significant poststroke upper/lower limb spasticity, in whom it has been decided to perform multidisciplinary treatment with BoNT-A + rehabilitation.\n* No previous treatment with BoNT-A.\n* Patient is able to follow the protocol.\n* Written informed consent.\n\nExclusion Criteria:\n\n* Neuromuscular disease.\n* Use of drugs that interfere with neuromuscular transmission.\n* Any other condition that could interfere with rehabilitation or evaluation of the results.\n* Diagnosis of spasticity not associated with stroke.\n* Pregnant or nursing mothers.\n* Prior participation in any other study in the 6 months before study entry","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"Post-stroke spasticity","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"overallOfficials":[{"name":"Ipsen Medical Director","affiliation":"Ipsen","role":"STUDY_DIRECTOR"}],"locations":[{"city":"Barcelona","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"city":"Bilbao","country":"Spain","geoPoint":{"lat":43.26271,"lon":-2.92528}},{"city":"Cadiz","country":"Spain","geoPoint":{"lat":36.52672,"lon":-6.2891}},{"city":"Cordoba","country":"Spain","geoPoint":{"lat":37.89155,"lon":-4.77275}},{"city":"Granada","country":"Spain","geoPoint":{"lat":37.18817,"lon":-3.60667}},{"city":"Huelva","country":"Spain","geoPoint":{"lat":37.26638,"lon":-6.94004}},{"city":"Las Palmas De G.C.","country":"Spain","geoPoint":{"lat":28.09973,"lon":-15.41343}},{"city":"Lleida","country":"Spain","geoPoint":{"lat":41.61674,"lon":0.62218}},{"city":"Madrid","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"city":"Murcia","country":"Spain","geoPoint":{"lat":37.98704,"lon":-1.13004}},{"city":"Palma de mallorca","country":"Spain","geoPoint":{"lat":39.56939,"lon":2.65024}},{"city":"Pontevedra","country":"Spain","geoPoint":{"lat":42.431,"lon":-8.64435}},{"city":"Salamanca","country":"Spain","geoPoint":{"lat":40.96882,"lon":-5.66388}},{"city":"San Sebastián","country":"Spain","geoPoint":{"lat":43.31283,"lon":-1.97499}},{"city":"Santiago","country":"Spain"},{"city":"Sevilla","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"city":"Valladolid","country":"Spain","geoPoint":{"lat":41.65518,"lon":-4.72372}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000009128","term":"Muscle Spasticity"}],"ancestors":[{"id":"D000009135","term":"Muscular Diseases"},{"id":"D000009140","term":"Musculoskeletal Diseases"},{"id":"D000009122","term":"Muscle Hypertonia"},{"id":"D000020879","term":"Neuromuscular Manifestations"},{"id":"D000009461","term":"Neurologic Manifestations"},{"id":"D000009422","term":"Nervous System Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M11775","name":"Muscle Spasticity","asFound":"Spasticity","relevance":"HIGH"},{"id":"M11782","name":"Muscular Diseases","relevance":"LOW"},{"id":"M11787","name":"Musculoskeletal Diseases","relevance":"LOW"},{"id":"M11769","name":"Muscle Hypertonia","relevance":"LOW"},{"id":"M22309","name":"Neuromuscular Manifestations","relevance":"LOW"},{"id":"M12094","name":"Neurologic Manifestations","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC05","name":"Musculoskeletal Diseases"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M4873","name":"Botulinum Toxins","relevance":"LOW"},{"id":"M250157","name":"abobotulinumtoxinA","relevance":"LOW"},{"id":"M20947","name":"Botulinum Toxins, Type A","relevance":"LOW"},{"id":"M250251","name":"incobotulinumtoxinA","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}